Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home News Equities

Novo Nordisk Partners With Orbis for Oral Biologic Pills Worth $1.4B; Eli Lilly Also Stakeholder in AI Drug Design Startup

by Team Lumida
September 17, 2026
in Equities
Reading Time: 4 mins read
A A
0
Novo Nordisk Partners With Orbis for Oral Biologic Pills Worth $1.4B; Eli Lilly Also Stakeholder in AI Drug Design Startup

1465073112

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp
  • Novo Nordisk agreed to partner with privately-held Danish startup Orbis Medicines on next-generation oral pills for heart and metabolic diseases in a deal worth up to $1.4 billion. Novo is also making an undisclosed strategic investment in Orbis. The partnership addresses Novo’s critical need to refill its drug pipeline ahead of generic competition for blockbuster injectable medications Ozempic and Wegovy.
  • Orbis’s technology uses artificial intelligence to design synthetic compounds that enable more efficient delivery of biologic medicines through oral pills. Current oral Wegovy requires far more drug ingredient than the injectable version because the stomach digests the pill as if it were food. Orbis technology aims to ensure more of the medicine enters the bloodstream, making oral versions more effective at lower doses.
  • Orbis is backed by top-tier venture investors and Eli Lilly & Co., Novo’s archrival in the weight-loss and metabolic disease market. Orbis previously raised €116 million ($133 million) in VC funding from Forbion and Novo Holdings (Novo’s biggest shareholder). Orbis stock surged 8.73% on announcement of Novo partnership, validating the startup’s AI-driven oral biologic platform as strategically valuable IP.
  • The partnership reflects broader competitive dynamics: both Novo and Lilly are racing to develop oral versions of injectable GLP-1 medicines (weight-loss, metabolic disease) as the market shifts toward oral administration. Novo’s investment in Orbis signals confidence that oral biologic technology is critical differentiator in next-generation drug competition against Lilly and others.

What Happened?

Novo Nordisk agreed to partner with Danish biotech startup Orbis Medicines on next-generation oral biologic pills worth up to $1.4 billion, with Novo making an undisclosed strategic investment. Orbis uses artificial intelligence to design compounds that enable more efficient oral delivery of biologic medicines, particularly Novo’s Ozempic and Wegovy analogs. Current oral Wegovy requires higher drug doses than injections because stomach digestion reduces bioavailability; Orbis technology improves oral absorption efficiency. Orbis is also backed by rival Eli Lilly & Co. as a stakeholder. Orbis stock surged 8.73% on announcement. Novo is refilling its drug pipeline ahead of generic competition for Ozempic and Wegovy blockbusters.

Why It Matters?

For Novo Nordisk shareholders, the partnership validates the company’s strategy to move from injectables to orals—a shift that could unlock massive additional patient populations (patients avoiding needles). For Orbis stakeholders and employees, the Novo partnership validates their AI drug-design platform at scale and de-risks the company’s path to market. For Eli Lilly shareholders, Lilly’s existing stake in Orbis positions the company to benefit from the oral biologic technology while competing with Novo. For the broader pharma market, the partnership signals that oral biologic delivery is the next competitive frontier—companies investing now in this technology will win market share in obesity and metabolic disease treatment.

What’s Next?

Monitor Novo’s pipeline announcements for additional Orbis compounds; if the company advances multiple oral biologic candidates, it would validate the partnership’s potential. Track Eli Lilly’s own oral biologic development; if Lilly accelerates programs using Orbis technology, it would signal dual competitive strategy. Watch for regulatory approvals of oral versions of Ozempic/Wegovy competitors; if oral formulations reach market before injectables decline, it could accelerate patient migration. Monitor Orbis valuation trajectory; if the startup fundraises again at higher valuation post-Novo partnership, it would validate the deal’s impact. Also track competitive responses from other pharma companies; if others invest in alternative oral biologic platforms (Amgen, Pfizer), it would signal sector-wide pivot to oral delivery.

Affected Tickers & Coins: NVO, ORBS, LLY

Source: Bloomberg

Previous Post

How to Bet on Oil Without Owning a Barrel: Retail Traders Navigate Crude Products From ETFs to Perpetual Futures

Next Post

US Stock Futures Rally Post-Fed as Oil Falls, Treasury Yields Decline; Nasdaq 100 Futures Up 1.1%, Tech Leads Rebound

Recommended For You

BofA’s Moynihan Says Deals Are Being Pushed Into 2027 as Anthropic’s Blockbuster IPO Crowds Out Smaller Listings

by Team Lumida
3 hours ago
Bank of America Q4 2024 Earnings Analysis

Bank of America CEO Brian Moynihan said some deals are slipping into 2027 as Anthropic’s IPO crowds out smaller listings, though the pipeline is full.

Read more

Take-Two Climbs More Than 3% Ahead of Thursday’s ‘GTA VI’ Launch, as Jefferies Reiterates a $300 Target and Says the Game ‘Is Just the Beginning’

by Team Lumida
3 hours ago

Take-Two rose more than 3% ahead of GTA VI’s Nov. 19 launch, as Jefferies kept a $300 target and preorders topped 12 million.

Read more

Buffett Gives Away $5.5 Billion of Berkshire Stock as Shares Rally More Than 19% This Quarter Against the S&P 500’s 1.2% Decline

by Team Lumida
3 hours ago
Lumida Wealth Whale Watch Q2’24 : Value Funds

Warren Buffett donated about $5.5 billion of Berkshire shares to four foundations as the stock hits records while the S&P 500 slips.

Read more

L3Harris Falls 4% After the Administration Ties the Nationwide FAA Ground Stop to Its Fiber Work, as About 18,000 US Flights Are Canceled and Airline Stocks Slip

by Team Lumida
3 hours ago

L3Harris fell 4% after officials tied Friday’s FAA ground stop to its maintenance work, as airlines tallied about 18,000 cancellations.

Read more

Nvidia Faces a $109 Billion Revenue Test in Kress’s First Call as Interim CEO, With the Stock Down Six Straight Weeks and Morgan Stanley Cutting Data-Center Estimates About 10%

by Team Lumida
3 hours ago

Nvidia reports Tuesday with Street eyeing $109.1 billion in revenue as interim CEO Kress faces China, neocloud and succession questions.

Read more

Petition to Reinstate Jensen Huang Tops 160,000 Signatures as Altimeter and Atreides Urge Nvidia’s Board to Keep His Return on the Table

by Team Lumida
11 hours ago
Nvidia Defies US Controls: $12 Billion AI Chip Sales in China

A petition backing Jensen Huang's return to Nvidia has topped 160,000 signatures, and major holders want the board to weigh all options.

Read more

Cisco Shares Drop 6% a Day After the Company Beats Estimates and Raises Hyperscaler AI-Infrastructure Revenue Guidance to $9 Billion

by Team Lumida
3 days ago

Cisco fell 6% on Friday, a day after beating estimates and raising its hyperscaler AI-infrastructure revenue outlook to $9 billion.

Read more

Apple Hits an Intraday Record of $360.80 and Tops $5.2 Trillion as Bernstein Calls It the ‘Costco’ of Tech and Keeps a $380 Target

by Team Lumida
3 days ago

Apple rose nearly 1% to an intraday record of $360.80 and a value above $5.2 trillion, as Bernstein kept an outperform rating and a $380 target.

Read more

Supreme Court Agrees to Hear Robinhood’s Challenge to a 2021 IPO Omission Lawsuit That Also Names Goldman and J.P. Morgan

by Team Lumida
3 days ago

The Supreme Court agreed to hear Robinhood’s challenge to a lawsuit over omitted 2021 IPO data, a case that also names Goldman Sachs and J.P. Morgan.

Read more

GOP Leaders Summon Huang to Testify and Threaten Subpoenas, as Nvidia’s Board Says It Has Not Yet Chosen a CEO Search Firm

by Team Lumida
3 days ago

Lawmakers summoned Jensen Huang to testify and threatened subpoenas, as Nvidia’s board said it has not yet chosen a firm to search for a permanent CEO.

Read more
Next Post
US Stock Futures Rally Post-Fed as Oil Falls, Treasury Yields Decline; Nasdaq 100 Futures Up 1.1%, Tech Leads Rebound

US Stock Futures Rally Post-Fed as Oil Falls, Treasury Yields Decline; Nasdaq 100 Futures Up 1.1%, Tech Leads Rebound

SEC Approval Boosts Crypto Funds: $1.2B Invested in a Week

Shorts Take $208 Million of a $345 Million Liquidation Wave as Bitcoin Holds $76,000 Through the Fed Hike

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

Tokenized Cash Breaks Into Mainstream — Spiko Raises $90 Million to Build on Blockchain What BlackRock Still Dominates in Traditional Finance

Tokenized Cash Breaks Into Mainstream — Spiko Raises $90 Million to Build on Blockchain What BlackRock Still Dominates in Traditional Finance

October 6, 2026

Nvidia Loses $220 Billion: What It Means for Your Investments

June 23, 2024
Nvidia CEO Reveals Secrets Behind AI Domination Amidst Fierce Competition

Nvidia Partner GMI Cloud Seeks $635 Million GPU-Backed Loan — One of Asia’s First Syndicated AI Infrastructure Financings

July 14, 2026

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Legacy
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Opinions
    • Investing Philosophy
    • Op-Ed
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Investing Philosophy
  • Latest
  • Legacy
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Op-Ed
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bank of America China Commercial Real Estate CPI data centers Donald Trump EARNINGS ELON MUSK Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Novo Nordisk Nuclear Energy Nvidia oil OpenAI private equity S&P 500 SEC Semiconductor stock market stock surge Tech Stocks tesla Trump Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018